Peptide Receptor Radiotherapy as a Potential Tool of Neoadjuvant Therapy in Patients with Inoperable Neuroendocrine Tumors (NETs) Abstract #290

Introduction: Neoadjuvant treatment is used as pre-surgical therapy in different cancers to decrease tumor size. PRRT can be a useful tool in neoadjuvant treatment of patients with well-differentiated NETs.
Aim(s): To assess using PRRT in primary inoperable NET and show neoadjuvant treatment results in downstaging of the tumor and option of surgery.
Materials and methods: Six patients - five foregut - four PNT, one midgut were included for PRRT every 6-9 weeks. Mean dose - 376 mCi. Tumor mean size was 96.2 mm. Only one patient had metastases to the liver. Cytoreduction chemotherapy was not used.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Anna Sowa-Staszczak

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1863 Outcome of Surgical Resection after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT) for Pancreatic Neuroendocrine Neoplasms: A Case-Matched Analysis
Introduction: Neoadjuvant Peptide receptor radionuclide therapy (NPRRT) can be an option for advanced pancreatic neuroendocrine neoplasms (PNEN) before surgery. Is not clear if NPRRT increases postoperative morbidity
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Francesca Muffatti
#889 Delayed Haematological Toxicity in Patients Treated with 177Lu-octreotate Peptide Receptor Radiotherapy (PRRT) for Metastatic Neuroendocrine Tumors (NETs)
Introduction: PRRT is associated with a high tumor control rate and early toxicity seems acceptable (haematological grade 3-4 toxicity: 11.3%). Long-term monitoring of haematological toxicity is unavailable.
Conference: 11th Annual ENETS Conference (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Olivia Hentic
#1505 A Blood-Based Multi-Transcript Test, the NETest, Predicts and Defines PRRT Efficacy in Neuroendocrine Tumors
Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective NET treatment. Predicting response is based on somatostatin receptor expression and efficacy evaluated by RECIST criteria. Both have limited accuracy. The NETest measures tumor activity in blood and correlates cell signaling and metabolism directly with tumor activity.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Professor Mark Kidd
Authors: Bodei L, Kidd M, Severi S, Drozdov I, ...
Keywords: NETest, PRRT
#101 Chronic Complications of Peptide Receptor Radionuclide Therapy (PRRT)- A Single Center Experience
Introduction: In the last decade, a new treatment modality, peptide receptor radionuclide therapy (PPRT), has been introduced for gastroenteropancreatic neuroendocrine tumor (GEPNET) patients with non-resectable or progressive disease. PRRT has been associated with several complications, including bone marrow suppression, renal toxicity and hepatic damage.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Merav Fraenkel
#395 Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) in North American Cohort of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors (mNETs)
Introduction: PRRT is an accepted treatment in Europe for patients (pts) with mNETs, but considered investigational in the USA.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Boris Naraev
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.